Terbinafine 1% cream 英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

terbinafine 1% cream

viatris uk healthcare ltd - terbinafine hydrochloride - cutaneous cream - 10mg/1gram

Terbinafine 250mg tablets 英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

terbinafine 250mg tablets

sigma pharmaceuticals plc - terbinafine hydrochloride - oral tablet - 250mg

Terbinafine 250mg tablets 英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

terbinafine 250mg tablets

waymade healthcare plc - terbinafine hydrochloride - oral tablet - 250mg

Terbinafine 250mg tablets 英国 - 英文 - MHRA (Medicines & Healthcare Products Regulatory Agency)

terbinafine 250mg tablets

noumed life sciences ltd - terbinafine hydrochloride - oral tablet - 250mg

TERBINAFINE tablet 美国 - 英文 - NLM (National Library of Medicine)

terbinafine tablet

remedyrepack inc. - terbinafine hydrochloride (unii: 012c11zu6g) (terbinafine - unii:g7riw8s0xp) - terbinafine tablets, usp are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (koh) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis. terbinafine tablets are contraindicated in patients with: •  history of allergic reaction to oral terbinafine because of the risk of anaphylaxis [see adverse reactions (6.2)] •  chronic or active liver disease [see warnings and precautions (5.1)] risk summary available data from postmarketing cases on the use of terbinafine tablets in pregnant women are insufficient to evaluate a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in animal reproduction studies, terbinafine did not cause malformations or any harm to the fetus when administered to pregnant rab

TERBINAFINE HYDROCHLORIDE tablet 美国 - 英文 - NLM (National Library of Medicine)

terbinafine hydrochloride tablet

nucare pharmaceuticals,inc. - terbinafine hydrochloride (unii: 012c11zu6g) (terbinafine - unii:g7riw8s0xp) - terbinafine tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium). prior to initiating treatment, appropriate nail specimens for laboratory testing [potassium hydroxide (koh) preparation, fungal culture, or nail biopsy] should be obtained to confirm the diagnosis of onychomycosis. terbinafine tablets are contraindicated in patients with: - history of allergic reaction to oral terbinafine because of the risk of anaphylaxis [see adverse reactions (6.2)] - chronic or active liver disease [see warnings and precautions (5.1)] pregnancy category b there are no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, and because treatment of onychomycosis can be postponed until after pregnancy is completed, it is recommended that terbinafine tablets not be initiated during pregnancy. oral reproducti